Compare LQDA & URBN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | LQDA | URBN |
|---|---|---|
| Founded | 2004 | 1970 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Clothing/Shoe/Accessory Stores |
| Sector | Health Care | Consumer Discretionary |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.5B | 6.2B |
| IPO Year | 2020 | 1995 |
| Metric | LQDA | URBN |
|---|---|---|
| Price | $68.49 | $75.26 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 11 | 12 |
| Target Price | $41.00 | ★ $86.91 |
| AVG Volume (30 Days) | 963.9K | ★ 1.0M |
| Earning Date | 05-08-2026 | 05-20-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 51.81 | 18.78 |
| EPS | 1.26 | ★ 4.06 |
| Revenue | $158,320,000.00 | ★ $6,165,376,000.00 |
| Revenue This Year | $278.87 | $10.67 |
| Revenue Next Year | $57.13 | $7.01 |
| P/E Ratio | $56.31 | ★ $18.42 |
| Revenue Growth | ★ 1031.18 | 11.07 |
| 52 Week Low | $21.35 | $59.54 |
| 52 Week High | $93.61 | $85.43 |
| Indicator | LQDA | URBN |
|---|---|---|
| Relative Strength Index (RSI) | 47.51 | 46.24 |
| Support Level | $62.86 | $73.94 |
| Resistance Level | $92.35 | $77.81 |
| Average True Range (ATR) | 2.78 | 2.19 |
| MACD | 0.69 | -0.41 |
| Stochastic Oscillator | 66.74 | 17.43 |
Liquidia Corp is a United States-based biopharmaceutical company focused on the development, manufacturing, and commercialization of products that address unmet patient needs, with the current focus directed towards the treatment of pulmonary hypertension (PH) and pulmonary hypertension associated with interstitial lung disease. It conducts research, development, and manufacturing of novel products by applying its proprietary PRINT technology, a particle engineering platform, to enable the precise production of uniform drug particles. Its product includes YUTREPIA (treprostinil) inhalation powder, for the treatment of pulmonary arterial hypertension. The company also conducting studies on L606, an investigational, liposomal formulation of treprostinil.
Founded in 1970, Philadelphia-based Urban Outfitters is a multibrand apparel and home goods retailer that operates nearly 800 stores and e-commerce in the US, which accounts for about 87% of sales, as well as in other regions. Its retail nameplates are Urban Outfitters (22% of fiscal 2026 sales), Free People/Movement (26%), and Anthropologie (42%). Retail accounted for 86% of fiscal 2026 revenue, but Urban Outfitters also sells products through a wholesale operation, owns some restaurants, and operates a fast-growing clothing rental and resale business called Nuuly (9% of sales). Urban Outfitters primarily markets to young adults and offers products across apparel (66% of sales), home goods (16% of sales), accessories (13% of sales), and more.